Current strategies to inhibit this lung cancer cell-surface glycocalyx shield and form of CD8+ T cell repression include conjugating sialidase enzyme in a bispecific agent to a tumor-surface target (e.g., PD-L1 or B7-H3). Here, CD8A is linked to neoplasm.